Additionally, it is important to note that there was reduced NLRP3/caspase-1 complex activity (Figure 7T) in the transgenic tumor-bearing mice upon treatment with anti-CTLA4 in all three cohorts. The gene discussed is CASP1; the disease is neoplasm.